{"id":240,"date":"2020-05-27T04:31:54","date_gmt":"2020-05-27T04:31:54","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=240"},"modified":"2020-05-27T04:31:54","modified_gmt":"2020-05-27T04:31:54","slug":"26-may-2020-tocilizumab-rapid-beneficial-effect-on-fever-and-inflammatory-markers","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/26-may-2020-tocilizumab-rapid-beneficial-effect-on-fever-and-inflammatory-markers\/","title":{"rendered":"(26 May 2020) Tocilizumab-  rapid beneficial effect on fever and inflammatory markers"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in<br \/>\nMilan, Italy<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.ejim.2020.05.011<\/p>\n<p class=\"\">In this open-label prospective study&nbsp; clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab are described. Forty-five patients (88%) were on high-flow oxygen supplementation, six of whom with invasive ventilation. From baseline to day 7 after tocilizumab, a dramatic drop of body temperature and CRP value with a significant increase in lymphocyte count (p&lt;0.001) was observed. Over a median follow-up time of 34 days from tocilizumab, 34 patients (67%) showed an improvement in their clinical severity class; 31 were discharged; 17 (33%) showed a worsening of their clinical status, of these 14 died (27%). The mortality rate was significantly<br \/>\nassociated with mechanical ventilation at baseline (83.3% vs 20% of patients on non-invasive oxygen support; p=0.0001). The most frequent side effects were an increase of hepatic enzymes (29%), thrombocytopenia (14%), and serious bacterial and fungal infections (27%). Tocilizumab exerts a rapidly beneficial effect on fever and inflammatory markers, although no significant impact on the clinical outcome can be inferred by our results. Critically ill patients seem to have a high risk of serious infections with this drug.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy https:\/\/doi.org\/10.1016\/j.ejim.2020.05.011 In this open-label prospective study&nbsp; clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab are described. Forty-five patients&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/26-may-2020-tocilizumab-rapid-beneficial-effect-on-fever-and-inflammatory-markers\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(26 May 2020) Tocilizumab-  rapid beneficial effect on fever and inflammatory markers&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/240"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=240"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/240\/revisions"}],"predecessor-version":[{"id":241,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/240\/revisions\/241"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}